Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

Inclusion Criteria:

• Age ≥18 years.

• Patients with histologically- or cytologically-proven, surgically unresectable,locally advanced pancreatic adenocarcinoma.

• If the patient does not have a diagnostic biopsy that is adequate for review at ourinstitution, the patient must agree to a research core biopsy to be performed atJohns Hopkins.

• If the patient's available imaging is not adequate for review by our institution,the patient must agree to a repeat imaging to be performed at Johns Hopkins.

• Patients cannot have had any prior therapy for the locally advanced pancreaticadenocarcinoma.

• ECOG performance status 0 or 1

• Life expectancy greater than 3 months.

• Able to swallow pills or capsules.

• Patient must have adequate organ function defined by the study-specified laboratorytests.

• Patients must be eligible to receive FOLFIRINOX-based chemotherapy.

• Patients must be willing to be treated with stereotactic body radiation therapy (SBRT) only at Johns Hopkins Hospital.

• Patients must be willing to undergo a core biopsy of the pancreatic cancer.

• Patients must be willing to undergo a biopsy of the pancreatic cancer if the patientis not deemed a surgical candidate during the pre-surgical evaluation.

• Must use acceptable form of birth control while on study.

• Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

• Have had non-FOLFIRINOX-based chemotherapy for the pancreatic cancer.

• Have received any anti-neoplastic biologics, vaccines or hormonal treatment,including investigational drugs, within 28 days of the first dose of study.

• History of past treatment with immunotherapy agents prior to initial enrollment intothis study (including, but not limited to: IL-2, interferon, anti-PD-1, anti-PD-L1,anti-PD-L2, anti-CD137, anti-OX-40, anti-CD40, anti-CTLA-4 or anti-CCR2/5 drugs).

• Have had prior organ or tissue allograft or allogeneic bone marrow transplantation,including corneal transplants.

• Is currently participating or has participated in a study of an investigationalagent or using an investigational device for the treatment of cancer.

• Current use of immunosuppressive medications within 14 days prior to studymedications.

• Have received any vaccine within 14 days prior to study medications.

• Receiving growth factors including, but not limited to, granulocyte-colonystimulating factor (G-CSF), GM-CSF, erythropoietin, within 14 days of the first doseof study medication.

• History of any autoimmune disease. Patients with thyroid disease will be allowed.

• Has a history of (non-infectious) pneumonitis or current pneumonitis.

• Has a pulse oximetry < 92% on room air.

• Requires the use of home oxygen.

• Patients with uncontrolled intercurrent illness including, but not limited to,myocardial infarction or stroke/transient ischemic attack within the past 6 months,uncontrolled infection, symptomatic congestive heart failure, unstable anginapectoris, cardiac arrhythmia, or psychiatric illness/social situations that wouldlimit compliance with study requirements.

• 12-lead electrocardiogram with QRS ≥ 120 msec, except right bundle branch block ;QTcF (QT corrected for heart rate using Fridericia's method) ≥ 480 msec, exceptright bundle branch block

• Has an active infection requiring systemic therapy.

• Infection with HIV or hepatitis B or C.

• Any concurrent malignancy other than non-melanoma skin cancer, non-invasive bladdercancer, early stage prostate cancer, or carcinoma in situ of the cervix.

• Current or recent (within 3 months of study treatment administration)gastrointestinal disease that could impact the absorption of study treatment.

• Any gastrointestinal surgery that is likely impact upon the absorption of studytreatment.

• Inability to tolerate oral medication.

• Unable to have blood drawn.

• Have had surgery within 28 days of the first dose of study medication.

• Prior use of strong/moderate CYP3A4 inhibitors or inducers within 28 days of thefirst dose of BMS-813160.

• Prior use of Class I antiarrhythmics within 28 days of first dose of studymedication.

• Has ascites requiring medical management.

• Presence of duodenal or gastric invasion by the tumor.

• Hypersensitivity reaction to any monoclonal antibody.

• Known allergy or hypersensitivity to study drugs or any of their components of thestudy arm that participant is enrolling.

• Woman who are pregnant or breastfeeding.

• Patient is unwilling or unable to follow the study schedule for any reason.